Literature DB >> 21564093

The new Ghent criteria for Marfan syndrome: what do they change?

L Faivre1, G Collod-Beroud, L Adès, E Arbustini, A Child, B L Callewaert, B Loeys, C Binquet, E Gautier, K Mayer, M Arslan-Kirchner, M Grasso, C Beroud, D Hamroun, C Bonithon-Kopp, H Plauchu, P N Robinson, J De Backer, P Coucke, U Francke, O Bouchot, J E Wolf, C Stheneur, N Hanna, D Detaint, A De Paepe, C Boileau, G Jondeau.   

Abstract

The diagnosis of Marfan syndrome (MFS) is challenging and international criteria have been proposed. The 1996 Ghent criteria were adopted worldwide, but new diagnostic criteria for MFS were released in 2010, giving more weight to aortic root aneurysm and ectopia lentis. We aimed to compare the diagnosis reached by applying this new nosology vs the Ghent nosology in a well-known series of 1009 probands defined by the presence of an FBN1 mutation. A total of 842 patients could be classified as MFS according to the new nosology (83%) as compared to 894 (89%) according to the 1996 Ghent criteria. The remaining 17% would be classified as ectopia lentis syndrome (ELS), mitral valve prolapse syndrome or mitral valve, aorta, skeleton and skin (MASS) syndrome, or potential MFS in patients aged less than 20 years. Taking into account the median age at last follow-up (29 years), the possibility has to be considered that these patients would go on to develop classic MFS with time. Although the number of patients for a given diagnosis differed only slightly, the new nosology led to a different diagnosis in 15% of cases. Indeed, 10% of MFS patients were reclassified as ELS or MASS in the absence of aortic dilatation; conversely, 5% were reclassified as MFS in the presence of aortic dilatation. The nosology is easier to apply because the systemic score is helpful to reach the diagnosis of MFS only in a minority of patients. Diagnostic criteria should be a flexible and dynamic tool so that reclassification of patients with alternative diagnosis is possible, requiring regular clinical and aortic follow-up.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21564093     DOI: 10.1111/j.1399-0004.2011.01703.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  26 in total

1.  Identification of FBN1 gene mutations in Ukrainian Marfan syndrome patients.

Authors:  Rustam Zhurayev; Dorien Proost; Dmytro Zerbino; Viktor Fedorenko; Josephina A N Meester; Lut VAN Laer; Bart L Loeys
Journal:  Genet Res (Camb)       Date:  2016-10-11       Impact factor: 1.588

2.  A novel fibrillin 1 gene mutation leading to marfan syndrome with minimal cardiac features.

Authors:  E Martínez-Quintana; F Rodríguez-González; P Garay-Sánchez; A Tugores
Journal:  Mol Syndromol       Date:  2014-02-27

Review 3.  Marfan Syndrome: oral implication and management.

Authors:  P Bollero; L Arcuri; M Miranda; L Ottria; R Franco; A Barlattani
Journal:  Oral Implantol (Rome)       Date:  2017-09-27

4.  Genetic dissection of marfan syndrome and related connective tissue disorders: an update 2012.

Authors:  S Hoffjan
Journal:  Mol Syndromol       Date:  2012-06-12

Review 5.  [Aneurysms of the ascending aorta and aortic arch].

Authors:  S Leontyev; M Misfeld; F W Mohr
Journal:  Chirurg       Date:  2014-09       Impact factor: 0.955

Review 6.  Marfan syndrome.

Authors:  Dianna M Milewicz; Alan C Braverman; Julie De Backer; Shaine A Morris; Catherine Boileau; Irene H Maumenee; Guillaume Jondeau; Arturo Evangelista; Reed E Pyeritz
Journal:  Nat Rev Dis Primers       Date:  2021-09-02       Impact factor: 65.038

Review 7.  Perspectives on the revised Ghent criteria for the diagnosis of Marfan syndrome.

Authors:  Yskert von Kodolitsch; Julie De Backer; Helke Schüler; Peter Bannas; Cyrus Behzadi; Alexander M Bernhardt; Mathias Hillebrand; Bettina Fuisting; Sara Sheikhzadeh; Meike Rybczynski; Tilo Kölbel; Klaus Püschel; Stefan Blankenberg; Peter N Robinson
Journal:  Appl Clin Genet       Date:  2015-06-16

8.  Prevalence, incidence, and age at diagnosis in Marfan Syndrome.

Authors:  Kristian A Groth; Hanne Hove; Kasper Kyhl; Lars Folkestad; Mette Gaustadnes; Niels Vejlstrup; Kirstine Stochholm; John R Østergaard; Niels H Andersen; Claus H Gravholt
Journal:  Orphanet J Rare Dis       Date:  2015-12-02       Impact factor: 4.123

9.  Musculo-skeletal abnormalities in patients with Marfan syndrome.

Authors:  Ali Al Kaissi; Elisabeth Zwettler; Rudolf Ganger; Simone Schreiner; Klaus Klaushofer; Franz Grill
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2013-01-29

Review 10.  When flexibility is not necessarily a virtue: a review of hypermobility syndromes and chronic or recurrent musculoskeletal pain in children.

Authors:  Marco Cattalini; Raju Khubchandani; Rolando Cimaz
Journal:  Pediatr Rheumatol Online J       Date:  2015-10-06       Impact factor: 3.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.